SpectraCure AB's financial performance is the most significant factor, heavily impacted by ongoing net losses and negative cash flows, contributing to a low overall score. Technical analysis further indicates bearish conditions, with the stock trading below key moving averages. The negative P/E ratio and lack of dividend yield weaken the valuation outlook, resulting in a low overall stock score.

SpectraCure AB (SPEC) vs. iShares MSCI Sweden ETF (EWD)

Market Cap

€105.75M

Dividend YieldN/A

Average Volume (3M)2.07M

Price to Earnings (P/E)―

Beta (1Y)-0.47

Revenue GrowthN/A

EPS Growth-10.85%

CountrySE

Employees16

SectorHealthcare

Sector Strength39

IndustryMedical - Devices

Share Statistics

EPS (TTM)-0.05

Shares Outstanding401,334,320

10 Day Avg. Volume1,156,813

30 Day Avg. Volume2,066,658

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)1.55

Price to Sales (P/S)0.00

P/FCF Ratio-4.68

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

SpectraCure AB Business Overview & Revenue Model

Company DescriptionSpectraCure AB (SPEC) is a medical technology company focused on developing innovative cancer treatment solutions. The company specializes in photodynamic therapy (PDT), a minimally invasive treatment method that uses laser technology to activate a photosensitive drug for the effective targeting and destruction of cancer cells. SpectraCure primarily targets hard-to-treat cancers, such as prostate cancer, with its proprietary Interstitial Photodynamic Therapy (IPDT) system designed to improve patient outcomes and reduce side effects associated with traditional cancer treatments.

How the Company Makes MoneySpectraCure AB generates revenue through the commercialization of its Interstitial Photodynamic Therapy (IPDT) system. The company sells its IPDT equipment and related consumables to hospitals, clinics, and cancer treatment centers. Additionally, SpectraCure may engage in strategic partnerships and collaborations with medical institutions and research organizations to further develop and expand the application of its technology. Licensing agreements and service contracts for maintenance and training related to the use of its PDT systems also contribute to its income. The company may also receive funding through grants and investments aimed at advancing cancer treatment technologies.

SpectraCure AB Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	5.44M	318.00K	539.00K	0.00	1.21K	763.00
Gross Profit	8.91M	-9.22M	3.58M	1.39M	2.35M	2.62M
EBITDA	-19.54M	-20.97M	-22.27M	-20.43M	-12.88M	-11.35M
Net Income	-23.00M	-20.44M	-25.33M	-23.34M	-15.41M	-13.69M
Balance Sheet
Total Assets	121.00M	144.83M	162.42M	190.52M	210.53M	100.19M
Cash, Cash Equivalents and Short-Term Investments	18.27M	56.95M	93.18M	129.69M	157.24M	54.21M
Total Debt	5.14M	6.72M	2.70M	4.90M	5.36M	6.71M
Total Liabilities	14.15M	14.97M	12.12M	14.84M	13.32M	12.41M
Stockholders Equity	106.86M	129.86M	150.30M	175.68M	197.22M	87.78M
Cash Flow
Free Cash Flow	-37.10M	-34.45M	-33.08M	-27.09M	-19.99M	-25.18M
Operating Cash Flow	-21.82M	-18.68M	-22.96M	-18.60M	-9.40M	-10.05M
Investing Cash Flow	-15.28M	-15.56M	-11.35M	-8.49M	-10.58M	-15.13M
Financing Cash Flow	-1.57M	-1.99M	-2.20M	-453.00K	123.02M	34.32M

SpectraCure AB Technical Analysis

Technical Analysis Sentiment

Negative

Last Price0.26

Price Trends

50DMA

0.36

Negative

100DMA

0.59

Negative

200DMA

0.74

Negative

Market Momentum

MACD

-0.04

Negative

RSI

44.05

Neutral

STOCH

44.90

Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SPEC, the sentiment is Negative. The current price of 0.26 is below the 20-day moving average (MA) of 0.29, below the 50-day MA of 0.36, and below the 200-day MA of 0.74, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 44.05 is Neutral, neither overbought nor oversold. The STOCH value of 44.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SPEC.

SpectraCure AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (52)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.53B	0.32	-61.76%	2.28%	16.60%	1.56%
CLS.B	47 Neutral	€80.98M	―	-79.12%	―	86.02%	93.34%
CLS.B	47 Neutral	€80.98M	―	-79.12%	―	86.02%	93.34%
ACARIX	46 Neutral	kr361.14M	―	-88.97%	―	-0.61%	54.19%
SPEC	43 Neutral	€105.75M	―	-20.45%	―	―	-10.85%
QLINEA	43 Neutral	kr412.14M	―	-159.24%	―	-22.50%	76.74%
QLINEA	43 Neutral	kr412.14M	―	-159.24%	―	-22.50%	76.74%
SCIB	43 Neutral	kr126.86M	―	-209.61%	―	27.78%	43.32%
HEART	34 Underperform	kr68.48M	―		―	―	―

* Healthcare Sector Average

Performance Comparison

SE:SPEC

SpectraCure AB

0.26

-0.73

-73.57%

SE:ACARIX

Acarix AB

0.35

-0.15

-30.86%

SE:CLS.B

Clinical Laserthermia Systems AB Class B

3.19

-2.52

-44.13%

SE:CLS.B

Clinical Laserthermia Systems AB Class B

3.19

-2.52

-44.13%

SE:QLINEA

Q-linea AB

0.06

-0.50

-88.75%

SE:QLINEA

Q-linea AB

0.06

-0.50

-88.75%

SE:SCIB

SciBase Holding AB

0.38

-0.12

-24.40%

SE:HEART

Scandinavian Real Heart AB

13.70

-23.30

-62.97%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 25, 2025